Abstract
Emulating N95 protection with air filtration (or ventilation) requires 95% relative reduction of particles (20x) at all distances from the airborne particulate source e.g. person infected with COVID-19. Although not universally used, respirators are useful for reducing risk to both near-field and far-field exposures, whereas air filtration can only mitigate far-field exposure in a well-mixed environment, not near-field. To mitigate COVID infection risk, there is a wide range of air change per hour (ACH) recommendations from public health agencies (CDC, CDPH, etc.) ranging from 2 to 12 ACH. Tracking the removal of an airborne contaminant as a function of time can be used to measure ACH but is cumbersome and generally not possible in occupied rooms such as a classroom or home. Instead we use an optical particle counter to track decay rate of ambient aerosols (0.3□μm diameter) and measure ACH in a room (from surface deposition and air filtration) and in a whole, multi-room house (from air filtration). The rate of surface deposition in an unventilated room without HVAC ventilation or air filtration enabled was measured to be 0.6 ACH, and at least 12 ACH would be required to reduce exposures that emulate protection of N95 respirators (95%) at far-field. With air filtration enabled, 6-12 ACH was measured using ambient aerosols with one or more HEPA purifiers ($299-$999) or Do-It-Yourself (DIY) air purifiers ($55-$160) in each room. The resultant clean air delivery rate (CADR) per $100 varied from below 100 cfm to above 300 cfm with noise generated from 53 dBA to 63 dBA among these purifiers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
